Lixte, a US biotechnology company, announced on Friday that it had signed a collaboration agreement with Swiss pharmaceutical giant Roche and the Netherlands Cancer Institute (NKI).

The California-based company explains that it plans to start a clinical trial with its two partners in the treatment of metastatic colon cancer.

The trial will focus on the form of the disease with low microsatellite instability (MSI), which accounts for 85% of colorectal cancers.

The study will evaluate the efficacy of the combination of LB-100, Lixte's lead drug candidate, and Roche's blockbuster anticancer drug Tecentriq, with the latter also providing funding for clinical testing.

Copyright (c) 2024 CercleFinance.com. All rights reserved.